Piklozotan

Piklozotan
(IUPAC) ime
	3-hloro-4-[4-[4-(2-piridinil)-1,2,3,6-tetrahidropiridin-1-il]butil]-1,4-benzoksazepin-5(4H)-on
Klinički podaci
Identifikatori
CAS broj	182415-09-4
ATC kod	nije dodeljen
PubChem	9801640
UNII	FQE44HS7AH
Hemijski podaci
Formula	C23H24ClN3O2
Mol. masa	409,909 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C23H24ClN3O2/c24-22-17-29-21-9-2-1-7-19(21)23(28)27(22)14-6-5-13-26-15-10-18(11-16-26)20-8-3-4-12-25-20/h1-4,7-10,12,17H,5-6,11,13-16H2 ; Key: URMTUEWUIGOJBW-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	Nije kontrolisana supstanca

Piklozotan (SUN-N4057) je selektivni parcijalni agonist 5-HT_1A receptora, koji ima neuroprotektivno dejstvo u životinjskim studijama.^[3] On je bio u ranim kliničkim ispitivanjima za tretman akutnog moždanog udara.^[4]^[5]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Kamei, K.; Maeda, N.; Nomura, K.; Shibata, M.; Katsuragi-Ogino, R.; Koyama, M.; Nakajima, M.; Inoue, T. i dr.. (2006). „Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan.”. Bioorganic & Medicinal Chemistry 14 (6): 1978–1992. DOI:10.1016/j.bmc.2005.10.046. PMID 16290165.
↑ Ferro, J.; Dávalos, A. (2006). „Other neuroprotective therapies on trial in acute stroke”. Cerebrovascular diseases (Basel, Switzerland) 21 Suppl 2 (2): 127–130. DOI:10.1159/000091712. PMID 16651823.
↑ Mondick, J.; Oo, C.; Patel, D.; Fujitani, T.; Shimizu, K.; Barrett, J. (2009). „Population pharmacokinetics of the selective serotonin 5-HT1A receptor partial agonist piclozotan”. American journal of therapeutics 16 (2): 106–115. DOI:10.1097/MJT.0b013e31816b8c85. PMID 19300037.

	Portal Medicina
	Portal Hemija